Navigation Links
RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
Date:9/11/2009

MIAMI, Sept. 11 /PRNewswire/ -- RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM). Two of the firm's most popular product offerings, Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS capsules already use the technology in their manufacture. The use of this preparation method ensures the rapid and effective absorption of active ingredients.

"We're very pleased that the U.S. Patent and Trademark Office has recognized HerbaZorb as a patentable delivery system that allows herbal supplements and functional foods to be absorbed with full potency intact," said Mark Lubin, founder of RZN Nutraceuticals, Inc., and a 25-year veteran biomedical engineer and research scientist in the fields of orthopedics, joint diseases, implantable cardiac devices, materials science and medical chemistry.

Among the proprietary characteristics of HerbaZorb noted in the patent application are that it protects beneficial phytochemicals of herbs and herbal extracts from being digested prior to entering the bloodstream, providing a significant advantage to both producers of herbal products and those who consume them. "The basis for our patent is that our delivery system represents a breakthrough in the field of bioavailability, the process by which active ingredients are delivered to the bloodstream intact, ensuring their maximum usefulness in the body." Mr. Lubin commented.

According to company President Robert Hunt, "It is very satisfying to gain this important recognition for HerbaZorb, especially as we continue making the process available to other manufacturers who want us to prepare their herbal ingredients using this new technology."

Clinical researchers have long studied the role absorption plays in the bioavailability of active ingredients ingested into the body. According to the Physician's Desk Reference, only 10 to 20 percent of vitamins and minerals taken orally in tablet form are actually absorbed into the bloodstream.

"My goal has always been to develop the most effective and natural pain relief formulations possible, which resulted in the Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS family of products," Mr. Lubin stated. "With the advances in absorption offered by HerbaZorb, we can ensure that everyone in the industry using herbal blends can benefit from maximum bioavailability so the active ingredients in them are utilized most fully by the human body."

RZN Nutraceuticals' products are marketed direct to natural accounts, through private label, catalogue sales, practitioner offices, health clubs and on company's website, www.rznnutra.com. Future distribution plans include national drug store chains and natural supplement outlets.

For more information on Migra-Zen Relief Plus(R) or the three Arthri-Zen Relief(R) formulations, visit www.rznnutra.com, or contact RZN President Robert Hunt 904-213-8232.

For media inquiries, contact Jennifer Bryan of Christie Communications (www.christiecomm.com) at 805-969-3744.


'/>"/>
SOURCE RZN Nutraceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
2. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
3. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
4. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
5. Nutraceuticals could prevent diabetes
6. Berkeley Premium Nutraceuticals Pushes Forward
7. UM receives grant to support graduate students in the family nurse practitioner program
8. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
9. CBM-US Receives $3 Million Grant To Fund HIV/AIDS Prevention and Care Efforts in Africa
10. Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri
11. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... a common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. ... of dealing with excess skin oil. “Oily skin is a challenge to many of my ... the oily shine while keeping the skin fresh and clean,” says Dr. Au. , What ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology: